FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2534625082> ?p ?o ?g. }

• W2534625082 abstract "BACKGROUND: In 2010 and 2011, U.S. atrial fibrillation (AF) patients had two choices for oral anticoagulation therapy. However, limited real world data exist as to the patient characteristics, usage patterns, and medication perceptions of patients on these newer treatments.OBJECTIVE: To describe and compare characteristics of AF patients who have used warfarin or the newer anticoagulant, dabigatran.METHODS: Patient surveys were conducted via phone or internet from September 2011 to November 2011. Study patients were ≥18 years old, had a diagnosis of AF, and have used either warfarin or the newer anticoagulant, dabigatran. Characteristics differences were tested using chi-squared and ANOVA for categorical and continuous variables, respectively.RESULTS: We surveyed 361 patients. Of those, 204 were warfarin users and 160 were newer anticoagulant users (NAU). Mean patient age was 65.1. Patients were predominantly male (68.7%) and non-Hispanic white (91.2%). Nearly half (44.0%) of patients were obese and more than half (58.0%) had a Charlson Comorbidity Index (CCI) of ≥1. Average number of years with an AF diagnosis was 7. Patients were taking 6.26 medications on average. NAU were more likely to be female (36.9% vs. 27.0%), younger (60.93 vs. 68.36 years), diagnosed more recently (5.78 vs. 8.10 years), and had more education compared to warfarin patients (all p<.05). Levels of obesity (31.9% vs. 53.4%) and CCI burden of ≥1 (51.9% vs. 62.7%) were lower among NAU (p<.05). NAU were more likely to use an OTC medication (38.7% vs. 12.1%) or both a prescription and OTC medication (11.3% vs. 4.3%) to treat stomach-related symptoms (p<.05). NAU were more likely to have had a discussion about their treatment options with their physicians (36.9% vs. 24.5%) rather than have their physician prescribing (60.6% vs. 73.5%) (p<.05). NAU were significantly less likely to have considered switching their medication (10.7% vs. 31.9%). Among those considered switching, cost (62.5%) and insurance coverage (18.8%) were the most common reasons for NAU, and inconvenience factors (“too much of a hassle”; 19.5% and “interfering with my lifestyle”; 12.2%) for warfarin users.CONCLUSIONS: There were some characteristic differences among AF patients. Understanding patients' characteristics may be the first step in helping patients to be adherent to their stroke prevention medications." @default.
• W2534625082 created "2016-10-28" @default.
• W2534625082 creator A5024917453 @default.
• W2534625082 creator A5054619542 @default.
• W2534625082 creator A5057623083 @default.
• W2534625082 creator A5077613669 @default.
• W2534625082 date "2012-04-01" @default.
• W2534625082 modified "2023-09-25" @default.
• W2534625082 title "Abstract 240: Survey of Patients With Atrial Fibrillation on the Use of Warfarin and the Newer Anticoagulant, Dabigatran" @default.
• W2534625082 hasPublicationYear "2012" @default.
• W2534625082 type Work @default.
• W2534625082 sameAs 2534625082 @default.
• W2534625082 citedByCount "0" @default.
• W2534625082 crossrefType "journal-article" @default.
• W2534625082 hasAuthorship W2534625082A5024917453 @default.
• W2534625082 hasAuthorship W2534625082A5054619542 @default.
• W2534625082 hasAuthorship W2534625082A5057623083 @default.
• W2534625082 hasAuthorship W2534625082A5077613669 @default.
• W2534625082 hasConcept C126322002 @default.
• W2534625082 hasConcept C2776301958 @default.
• W2534625082 hasConcept C2778205648 @default.
• W2534625082 hasConcept C2778661090 @default.
• W2534625082 hasConcept C2778810321 @default.
• W2534625082 hasConcept C2779159551 @default.
• W2534625082 hasConcept C2779161974 @default.
• W2534625082 hasConcept C71924100 @default.
• W2534625082 hasConceptScore W2534625082C126322002 @default.
• W2534625082 hasConceptScore W2534625082C2776301958 @default.
• W2534625082 hasConceptScore W2534625082C2778205648 @default.
• W2534625082 hasConceptScore W2534625082C2778661090 @default.
• W2534625082 hasConceptScore W2534625082C2778810321 @default.
• W2534625082 hasConceptScore W2534625082C2779159551 @default.
• W2534625082 hasConceptScore W2534625082C2779161974 @default.
• W2534625082 hasConceptScore W2534625082C71924100 @default.
• W2534625082 hasLocation W25346250821 @default.
• W2534625082 hasOpenAccess W2534625082 @default.
• W2534625082 hasPrimaryLocation W25346250821 @default.
• W2534625082 hasRelatedWork W159163421 @default.
• W2534625082 hasRelatedWork W1622619388 @default.
• W2534625082 hasRelatedWork W1966943635 @default.
• W2534625082 hasRelatedWork W1997689261 @default.
• W2534625082 hasRelatedWork W2023819634 @default.
• W2534625082 hasRelatedWork W2026512965 @default.
• W2534625082 hasRelatedWork W2035728361 @default.
• W2534625082 hasRelatedWork W2064485755 @default.
• W2534625082 hasRelatedWork W2106954381 @default.
• W2534625082 hasRelatedWork W2152973076 @default.
• W2534625082 hasRelatedWork W2299197216 @default.
• W2534625082 hasRelatedWork W2410782318 @default.
• W2534625082 hasRelatedWork W2413416731 @default.
• W2534625082 hasRelatedWork W2438145529 @default.
• W2534625082 hasRelatedWork W2584413368 @default.
• W2534625082 hasRelatedWork W2666992979 @default.
• W2534625082 hasRelatedWork W2737374793 @default.
• W2534625082 hasRelatedWork W2991027958 @default.
• W2534625082 hasRelatedWork W2997939247 @default.
• W2534625082 hasRelatedWork W3137018382 @default.
• W2534625082 hasVolume "5" @default.
• W2534625082 isParatext "false" @default.
• W2534625082 isRetracted "false" @default.
• W2534625082 magId "2534625082" @default.
• W2534625082 workType "article" @default.